Corrigendum: Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open‐label, parallel‐group, non‐inferiority phase III trail
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsErythropoietin and Anemia Treatment · Hemoglobinopathies and Related Disorders · Pharmacological Effects and Toxicity Studies
In the article titled, “Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open‐label, parallel‐group, non‐inferiority Phase III trail” published in pages 59‐70, issue 1, vol. 8 of Chronic Diseases and Translational Medicine,1 the information of trial registration at the end of Abstract is missing. The registration information should be: This study has been registered on www.chinadrugtrials.org.cn, registered number CTR20130080.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Chen, N , Xing, C , Niu, J , et al. Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: a randomized, open‐label, parallel‐group, non‐inferiority phase III trail. Chronic Dis Transl Med 2022; 8: 59‐70. 10.1002/cdt 3.13 35620165 PMC 9128564 · doi ↗ · pubmed ↗